MAIT Engagers: Bypassing Treg Suppression & CRS in Solid Tumours
- Exploring how MAIT Engagers selectively activate cytotoxic T cells without engaging CD4⁺ regulatory T cells, preventing tumour-localised immune dampening
- Preventing CRS without CD4 binding – discussing how MAIT Engagers are designed to prevent systemic immune overstimulation by avoiding broad T cell activation
- Redefining T cell redirection – as a next-gen alternative to CD3-based approaches, seeing how MAIT Engagers offer a strategic leap in precision, potency, and safety in immune-oncology